1982
Immunological and physiological responses to whole-body hyperthermia.
Bull J, Lees D, Schuette W, Smith R, Glatstein E, DeVita V. Immunological and physiological responses to whole-body hyperthermia. National Cancer Institute Monograph 1982, 61: 177-81. PMID: 7177176.Peer-Reviewed Original Research
1977
Risk of new cancers in patients with Hodgkin's disease
Arseneau J, Canellos G, Johnson R, Devita V. Risk of new cancers in patients with Hodgkin's disease. Cancer 1977, 40: 1912-1916. PMID: 907993, DOI: 10.1002/1097-0142(197710)40:4+<1912::aid-cncr2820400823>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseAcute nonlymphocytic leukemiaNew cancersActive Hodgkin's diseaseLong-term complicationsSecond malignant tumorsReports of casesNational Cancer InstituteDirect cellular damageSynergistic carcinogenic effectPotential contributory factorsFurther immunosuppressionUntreated patientsImmunologic abnormalitiesTerm complicationsImproved survivalHD patientsImmunosuppressive factorsNonlymphocytic leukemiaMalignant diseaseMalignant tumorsCancer InstitutePatientsCytotoxic drugsTherapeutic interventions
1972
A decade of combination chemotherapy of advanced Hodgkin's disease
Devita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsAdvanced Hodgkin's diseaseComplete remission rateHodgkin's diseaseRemission rateRemission durationCombination chemotherapySingle agentLonger disease-free intervalDisease-free intervalAcute childhood leukemiaNew treatment programCombination of drugsComplete remissionComplete respondersCooperative trialsStage IIIChildhood leukemiaEffective drugsTreatment programTherapyUse of combinationsDiseasePilot studyFurther treatmentRemission